Biozen Unveils Breakthrough Cuffless Blood Pressure Technology at AHA 2026

Biozen, LLC, a pioneering digital health company based in Oklahoma City, is set to present significant advancements in its innovative cuffless blood pressure measurement technology at the upcoming American Heart Association's (AHA) Scientific Sessions 2026. The event is scheduled for November 6-9 in Chicago, and Biozen’s Chief Scientific Officer, Dr. Omer Inan, will unveil the findings through a moderated digital poster presentation on November 7 at 9:29 a.m. CT.

This presentation comes on the heels of a notable achievement for Biozen, as its flagship device, the BP1000, secured the title of the first FDA-cleared cuffless device in the United States, capable of delivering calibration-free blood pressure readings directly from the fingertip. Employing a unique technology platform that integrates fingertip oscillometry, Biozen’s device combines pressure and optical sensing with advanced physiology-informed algorithms to accurately measure both systolic and diastolic blood pressure.

The capacity to measure blood pressure without the need for a traditional cuff has been a game-changer in the industry. According to Dikran Tourian, CEO of Biozen, “The industry keeps asking whether accurate blood pressure measurement without a cuff is possible. Biozen has already answered that question.” This bold assertion encapsulates the essence of Biozen’s commitment to redefining health technology — not merely estimating blood pressure through indirect methods but providing a clinically validated alternative that is both convenient and precise.

Dr. Inan emphasized the core principle driving Biozen’s technology: clinical accuracy. He stated, “Clinical accuracy has always been the foundation of our technology. Our focus now is on continuously refining its performance while maintaining the measurement principles that ensure reliability.” The findings presented at the AHA will reflect this ongoing dedication to innovation and improvement.

Beyond its standalone capabilities, Biozen’s advanced platform is designed for seamless integration with wearables, smartphones, and various connected health technologies. The versatility of the BP1000 opens new avenues for personal health monitoring, providing users with immediate access to reliable blood pressure data without the constraints traditionally associated with cuffs.

The presentation at the AHA will take place in Clinical Science Zone 1 located in the Science & Technology Hall at the McCormick Place Convention Center. Attendees can locate Moderated Digital Poster 9 (MDP0118) in South Hall, Level 3. This event represents an excellent opportunity for researchers, clinicians, and health technology enthusiasts to experience firsthand the revolution in blood pressure management that Biozen is championing.

In conclusion, Biozen is not just about innovation; it represents a new era in healthcare technology. With over 68 granted patents in the U.S. and internationally to protect their revolutionary designs, the company is vigorously leading the charge toward more effective and accessible health monitoring solutions. For further details about Biozen and its cutting-edge blood pressure technology, interested parties are encouraged to visit biozen.com.

About Biozen

Biozen is a privately held digital health company headquartered in Oklahoma City, Oklahoma, with R&D operations in Atlanta, Georgia. The company specializes in developing cutting-edge cuffless blood pressure technologies, aiming to reshape how blood pressure readings are conducted globally.